Avalyn Pharma, a Boston-based company focused on inhaled therapies for lung diseases, has outlined plans to advance a pipeline built around reformulated treatments for pulmonary fibrosis. The company’s lead candidates include AP01, an inhaled version of pirfenidone intended for progressive pulmonary fibrosis, and AP02, an inhaled form of nintedanib designed for idiopathic pulmonary fibrosis (IPF).
In addition, Avalyn is developing AP03, a preclinical program combining both drugs into a single inhaled therapy, an approach that has not been achievable with oral formulations due to additive side effects. These programs are positioned within the company’s broader effort to adapt existing treatments into inhaled formats.
Pirfenidone and nintedanib are both approved as oral therapies but are associated with a range of side effects. Pirfenidone, marketed as Esbriet, has been linked to upper respiratory tract infections, sensitivity to sunlight, and liver-related complications. Nintedanib, sold as Ofev, has been associated with liver problems, gastrointestinal issues including diarrhea, nausea, and vomiting, as well as risks such as heart attack, stroke, and bleeding events.
Avalyn is pursuing inhaled delivery of these drugs with the aim of targeting the lungs directly while limiting exposure in other tissues. This approach is intended to focus drug activity in the lungs rather than distributing it throughout the body.
The company disclosed in an April 23 S-1 filing that it is seeking to raise approximately $181.8 million through an initial public offering. The total amount could increase to $209.7 million if underwriters exercise their option to purchase additional shares. Avalyn plans to offer around 11.8 million shares priced between $16 and $18, with a midpoint assumption of $17 per share. The company expects its stock to trade under the ticker AVLN, as detailed in the filing.
According to the filing, the proceeds from the offering are intended to support the continued development of its clinical and preclinical programs. Avalyn has indicated that approximately $150 million will be allocated to advance AP01 through Phase 2b topline data and into Phase 3 development. A further $90 million is expected to fund AP02 through its ongoing Phase 2 trial and into Phase 3. The company has also outlined that about $10 million will be used to move AP03 into clinical studies as development progresses.
As stated in the filing, “Avalyn Pharma is hoping to rake in around $182 million from an IPO, which the biotech will use to take its inhaled versions of approved drugs for respiratory conditions into late-stage studies,” according to the company’s regulatory disclosure.
Avalyn reported that it had $138.5 million in cash at the beginning of the year. The company has also raised funding through private rounds, including a $100 million Series D financing in July 2025 backed by Novo Holdings. Earlier rounds included a $175 million Series C in 2023 and a $35.5 million Series B in 2020.
The company employs 51 full-time staff, with 32 of those working in research and development roles. Avalyn is led by CEO Lyn Baranowski, who previously worked on respiratory medicines at Pearl Therapeutics, which were later acquired by AstraZeneca and subsequently commercialized.
Why Avalyn Is Going Public
The IPO will provide Avalyn with the capital needed to advance its clinical programs and expand research efforts. By entering the public markets, Avalyn aims to strengthen its financial foundation while increasing visibility among investors and strategic partners.
Clinical Development Priorities
The company plans to allocate a significant portion of the proceeds toward advancing its lead candidates through mid- and late-stage clinical trials. These programs are designed to address serious respiratory conditions where current treatment options remain limited or suboptimal.
Technology Platform and Differentiation
Its approach centers on reformulating established drugs into inhaled versions, enabling direct delivery to the lungs. This strategy can enhance drug efficacy at the site of disease while minimizing systemic exposure, which may reduce side effects and improve patient outcomes.
Competitive Landscape
The respiratory therapeutics market includes major pharmaceutical players as well as emerging biotech firms. Differentiation will depend on clinical data, ease of administration, and the ability to demonstrate clear advantages over existing oral or injectable therapies.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
